Immunai

Immunai

Immunai

Immunai is a biotech company with cutting-edge genomic technologies and machine-learning made to unravel the immune system.
Founded
2019
Raised
$295M
Follow us
Twitter followers
Latest funding Show all
$215,000,000
Venture capital (Series B) - 2021
Icon Ventures Piedmont Capital 8VC +3
$60,000,000
Venture capital (Series A) - 2021
Schusterman Foundation TLV Partners Viola Group +3
Team Size
1–10
Employees
$215,000,000 Venture capital (Series B)
TechCrunch

Immunai announces a $215M Series B as its ‘immune cell atlas’ matures

VentureBeat , TechCrunch

Immunai raises $60 million to analyze the immune system with AI

$60,000,000 Venture capital (Series A)
neurons.AI , AlleyWatch , neurons.AI

Immunai raises $60M as it expands from improving immune therapies to discovering new ones, too

neurons.AI

Immunai Joins 10x To Scale Single Cell Genomics

$20,000,000 Seed fund
the home of AI info , VentureBeat , Crunchbase News , +2

Immunai decloaks with $20M in seed funding to map immune system with machine learning